Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Exfoliated black phosphorus for biomedical applications

Project description

A novel nanomaterial-based therapy for prostate cancer

Prostate cancer is the second worldwide most common cancer in men and is conventionally treated with radiotherapy or radical prostatectomy. As an alternative treatment, the EU-funded PHOSMED project proposes to develop a smart nanomaterial composed of bidimensional black phosphorus. Apart from its unique properties, black phosphorus is biocompatible and biodegradable, rendering it suitable for biomedical applications. Importantly, it exhibits anti-proliferative, anti-inflammatory and regenerative properties with no side effects. Following validation on an in vivo animal model, PHOSMED scientists will bring their approach to the clinic to improve patients' quality of life and provide considerable economic benefits.

Objective

Since its discovery in 2014, bidimensional black phosphorus has raised a great scientific attention due to its unique structure and several exceptional attributes, such as peculiar optical and mechanical properties, excellent biocompatibility and biodegradation, which make it particularly attractive for biomedical applications.
Our studies performed during ERC-Advanced Grant (2015-2019) “Phosphorene functionalization: a new platform for advanced multifunctional materials - PHOSFUN” demonstrated the possibility to produce at large scale 2D BP with high purity grade at low cost by liquid exfoliation of bulk crystalline BP.
In addition to its low toxicity, we have proved that SMART BP treatment, obtained using our proprietary production process, has anti-proliferative effects as well as anti-inflammatory and regenerative properties in prostate tumours that can disrupt the treatment approach. Prostate cancer is the second most common cancer in men worldwide with about 1.3 million cases in 2018 and about 379,000 new deaths are expected by 2040. This makes prostate cancer a major public health concern.
As also stated by the European Urology Association, there is a need for more effective and cheaper early treatment options (alternative to radiotherapy or radical prostatectomy) that can bring a substantial decrease of healthcare costs.
Given the positive outcomes of lab tests performed by the PoC team while investigating the application in the health domain, we propose a patented prostate cancer treatment based on few-layer black phosphorus, SMART BP, that is a non-radioactive smart nanomaterial with no side effects (no irradiation, no toxicity, self-regeneration), improving patient’s quality of life and provide considerable economic benefits.
Within PHOSMED we intend to validate the effects of 2D BP on in vivo animal model, moving from TRL 3 to TRL 5 and paving the way to future scalability for new generation of no irradiation/no-toxic nanomedicine solutions.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

CONSIGLIO NAZIONALE DELLE RICERCHE
Net EU contribution
€ 150 000,00
Address
PIAZZALE ALDO MORO 7
00185 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)